Report Description Table of Contents How Is Fecal Calprotectin Testing Improving Intestinal Disease Diagnosis and Monitoring? – (Updated On: 10th-Nov-2026) According to Strategic Market Research, the Global Fecal Calprotectin Test Market was valued at USD 237 million in 2025 and is projected to reach USD 411.6 million by 2032, expanding at a CAGR of 8.2% during 2026–2032. Growth is supported by the use of fecal calprotectin testing to identify intestinal inflammation and monitor patients with Crohn's disease and ulcerative colitis. Increasing inflammatory bowel disease (IBD) diagnoses, repeated monitoring requirements, and the availability of laboratory-based and rapid stool tests are supporting market opportunities. More than 4.1 million U.S. adults with inflammatory bowel disease represent a substantial population for fecal calprotectin testing. According to the U.S. Centers for Disease Control and Prevention, approximately 4.11 million U.S. adults had diagnosed IBD during 2023–2024, including approximately 1.26 million with Crohn's disease and 3.15 million with ulcerative colitis. Fecal calprotectin testing helps physicians assess intestinal inflammation in patients with these conditions. The large patient population supports opportunities for initial diagnostic assessment and continued disease monitoring, although not every IBD patient undergoes the test. New inflammatory bowel disease cases are supporting additional opportunities for stool-based inflammation testing. A 2025 peer-reviewed analysis of Global Burden of Disease data estimated approximately 3.83 million people living with IBD worldwide in 2021, including 375,140 new cases during that year. More recent Global Burden of Disease 2023 research published in 2026 estimated approximately 1.39 million people living with IBD in Asia, with 160,997 new cases in 2023. Fecal calprotectin testing can help physicians investigate suspected intestinal inflammation and distinguish IBD from irritable bowel syndrome when combined with other clinical findings. New diagnoses create initial testing opportunities, while patients requiring long-term management may generate additional laboratory demand. Repeat testing is supporting continued demand for fecal calprotectin tests. According to the American Gastroenterological Association's 2023 guidelines, patients with Crohn's disease may need inflammation checks every 6–12 months, even when their symptoms are under control. Patients experiencing worsening symptoms may require more frequent testing. The guidelines for ulcerative colitis also recommend fecal calprotectin as one option for checking intestinal inflammation. Since patients may need testing several times during their treatment journey, repeated testing supports continued demand for diagnostic kits and laboratory services. New fecal calprotectin tests are improving the ability to detect intestinal inflammation. In May 2025, ALPCO launched its Calprotectin Immunoturbidimetric Assay in Europe. The company reported 90.5% sensitivity, meaning the test correctly identified approximately 91 out of 100 patients with the condition being evaluated, and 93.4% specificity, meaning it correctly identified approximately 93 out of 100 patients without that condition. ALPCO also began clinical testing of another automated version in the United States. These developments are increasing the availability of diagnostic options for hospitals and laboratories. Faster testing systems are helping laboratories process fecal calprotectin samples more efficiently. In July 2025, QuidelOrtho and BÜHLMANN Laboratories introduced the fCAL turbo assay on VITROS laboratory systems. The companies reported that the system can produce test results in less than 10 minutes, while reagents can remain usable on the analyzer for 90 days. In July 2026, the FDA also listed the BÜHLMANN fCAL turbo assay for use with the Roche cobas c 703 analyzer. These improvements allow laboratories to use established testing equipment and may help reduce the time and effort required to process samples. Market Outlook: The Global Fecal Calprotectin Test Market is projected to generate approximately USD 174.6 million in additional annual revenue by 2032. Future growth will depend on actual testing utilization, recurring clinical monitoring, reimbursement coverage, and the wider availability of automated assays. Manufacturers offering reliable test performance and compatibility with established laboratory analyzers are positioned to compete for reagent and diagnostic service demand. Companies such as BÜHLMANN Laboratories, ALPCO, QuidelOrtho, DiaSorin, Thermo Fisher Scientific, and Euroimmun operate within the broader competitive landscape. The principal commercial opportunities are expected to emerge from expanded laboratory access, clinically appropriate repeat testing, and efficient integration of fecal calprotectin assays into routine gastroenterology care. Which Fecal Calprotectin Test Market Segments Lead Adoption and Offer the Strongest Expansion Opportunities? By Product Type: ELISA Supports Routine Testing as Rapid Kits Shorten Turnaround Leading Subsegment – ELISA Test Kits ELISA (Enzyme-Linked Immunosorbent Assay) test kits hold the largest share of the Fecal Calprotectin Test Market, accounting for an estimated 42% market share, valued at USD 99.54 million in 2025, and are projected to grow at a CAGR of 6.7% during 2026–2032. ELISA kits are widely used for quantitative and semi-quantitative measurement of human calprotectin protein concentrations in stool samples. Their established role in laboratory-based testing supports the assessment and monitoring of intestinal inflammation, particularly in patients with inflammatory bowel disease. Fastest-Growing Subsegment – Rapid Test Kits Rapid Test Kits (RTKs) accounted for an estimated 33% share of the global fecal calprotectin test market, valued at USD 78.21 million in 2025, and are projected to register the fastest CAGR of 10.2% during 2026–2032. Primarily based on lateral flow immunoassay technology, rapid test kits enable fast, non-invasive detection and quantification of fecal calprotectin. Their growing use in point-of-care testing, gastrointestinal screening, and inflammatory bowel disease monitoring is supported by shorter turnaround times, simplified testing procedures, and faster clinical decision-making. By Test Method: Laboratories Anchor Testing as Home Collection Extends Monitoring Leading Subsegment – Laboratory-Based Testing Laboratory-based testing dominates the Fecal Calprotectin Test Market, accounting for an estimated 76% market share, valued at USD 180.12 million in 2025, and is projected to grow at a CAGR of 7.5% during 2026–2032. Laboratory-based fecal calprotectin testing measures the concentration of a calcium- and zinc-binding protein released by activated neutrophils into the gastrointestinal tract during inflammation. Its widespread use in diagnosing and monitoring inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, supports its leading market position. Fastest-Growing Subsegment – Home-Based Testing Home-based testing accounted for an estimated 5% share of the Fecal Calprotectin Test Market, valued at USD 11.85 million in 2025, and is projected to register the fastest CAGR of 12.0% during 2026–2032. Home-based fecal calprotectin testing is becoming increasingly important for remote monitoring of inflammatory bowel disease (IBD), particularly Crohn’s disease and ulcerative colitis. It allows patients to monitor intestinal inflammation from home, supports early identification of disease flare-ups, and helps healthcare providers make timely treatment adjustments while reducing frequent hospital visits. By Application: Repeat Monitoring and IBD–IBS Differentiation Expand the Role of Testing Leading Subsegment – Inflammatory Bowel Disease (IBD) Monitoring IBD monitoring accounted for the largest estimated market share of 44%, valued at USD 104.28 million in 2025, and is projected to grow at a CAGR of 8.5% during 2026–2032. Fecal calprotectin testing measures a protein released by neutrophils into the intestine during inflammation, providing a non-invasive method for assessing intestinal inflammation. Its widespread use in monitoring inflammatory bowel disease, evaluating treatment response, identifying potential flare-ups, and supporting clinical decisions strengthens its importance in routine IBD management. Fastest-Growing Subsegment – IBD Monitoring and IBD–IBS Differentiation IBD Monitoring and IBD–IBS Differentiation jointly register the highest CAGR of 8.5% during 2026–2032 in the Fecal Calprotectin Test Market. IBD–IBS Differentiation accounted for an estimated 22% market share, valued at USD 52.14 million in 2025. Increasing clinical use for monitoring disease activity and distinguishing inflammatory from functional bowel disorders supports wider adoption. By End User: Diagnostic Laboratories Handle Routine Testing as Self-Testing Extends Care at Home Leading Subsegment – Diagnostic Laboratories Diagnostic laboratories account for the largest share of the Fecal Calprotectin Test Market, holding an estimated 55% market share, valued at USD 130.35 million in 2025, and are projected to grow at a CAGR of 7.6% during 2026–2032. Their leading position is supported by their role in performing, standardizing, and reporting fecal calprotectin tests. Laboratories provide reliable measurement of this neutrophil-derived protein, helping clinicians assess intestinal inflammation, distinguish inflammatory bowel disease from functional gastrointestinal disorders, and monitor treatment response in patients with inflammatory bowel disease. Fastest-Growing Subsegment – Home Care Settings Home care settings account for an estimated 10% share of the Fecal Calprotectin Test Market, valued at USD 23.70 million in 2025, and are projected to register the fastest CAGR of 10.5% during 2026–2032. Home-based fecal calprotectin testing allows patients with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, to monitor intestinal inflammation without frequent laboratory visits. Increasing adoption of patient self-testing supports regular disease monitoring, early identification of inflammatory flare-ups, and more convenient long-term management of chronic intestinal conditions. By Geography: North American Guidelines and Wider Diagnostic Access in Asia-Pacific Support Adoption Leading Region – North America North America holds the largest share of the Fecal Calprotectin Test Market, accounting for an estimated 39% in 2025, valued at USD 92.43 million, and is projected to grow at a CAGR of 7.5% during 2026–2032. The region's leading position is supported by the growing integration of fecal calprotectin testing into routine gastroenterology practice, updated clinical guidelines, and increasing preference for non-invasive diagnostic methods. Wider adoption for inflammatory bowel disease monitoring and differentiating inflammatory conditions from functional gastrointestinal disorders further supports market expansion. Fastest-Growing Region – Asia-Pacific Asia-Pacific accounted for an estimated 24% of the global Fecal Calprotectin Test Market, valued at USD 56.88 million in 2025, and is projected to register the fastest regional CAGR of 10.3% during 2026–2032. Increasing prevalence of inflammatory bowel disease, growing awareness of gastrointestinal disorders, and greater clinical preference for non-invasive diagnostic testing are supporting regional market expansion. China, India, and Japan are witnessing increased adoption of fecal calprotectin testing for early intestinal inflammation assessment, disease monitoring, and distinguishing inflammatory bowel disease from functional gastrointestinal disorders. How Is Fecal Calprotectin Testing Used in Gastrointestinal Diagnosis and Patient Monitoring? 1. Differentiating Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS) Fecal calprotectin testing helps distinguish inflammatory conditions such as Crohn's disease and ulcerative colitis from IBS, which typically does not cause intestinal inflammation. A commonly used cutoff of 50 µg/g helps identify patients who may require further investigation. This application supports early clinical assessment and more appropriate gastroenterology referrals. 2. Screening and Gastrointestinal Patient Triage The test helps evaluate patients experiencing persistent diarrhea, abdominal discomfort, and changes in bowel habits. Low calprotectin concentrations can reduce the need for unnecessary colonoscopies in appropriately selected patients, while elevated results may indicate the need for further diagnostic evaluation. Its non-invasive nature makes it useful in primary care and outpatient gastroenterology services. 3. Monitoring Inflammatory Bowel Disease Activity Fecal calprotectin testing is widely used to monitor intestinal inflammation in patients with diagnosed Crohn's disease or ulcerative colitis. The American Gastroenterological Association (AGA) recognizes its clinical value in assessing disease activity alongside symptoms and other findings. Repeated measurements help evaluate treatment response, identify possible relapse, and guide decisions about further endoscopic assessment. 4. Assessing Treatment Response and Mucosal Healing Changes in fecal calprotectin levels provide clinicians with an indication of intestinal inflammatory activity during IBD treatment. Declining concentrations may support evidence of treatment effectiveness, while persistently elevated results can indicate ongoing inflammation. The test is particularly relevant for patients receiving biologic therapies and other long-term IBD treatments. 5. Evaluating Chronic Diarrhea and Other Gastrointestinal Symptoms Fecal calprotectin testing supports the investigation of chronic diarrhea, unexplained abdominal pain, and suspected intestinal inflammation. Elevated results may occur in gastrointestinal infections, including Clostridioides difficile, as well as other inflammatory conditions. Results are interpreted alongside clinical findings and additional diagnostic tests to identify the underlying cause. Which Companies Are Leading Innovation and Competition in the Fecal Calprotectin Test Market? BÜHLMANN Laboratories AG – Leading Specialist in Fecal Calprotectin Testing BÜHLMANN Laboratories AG is a prominent specialist in fecal calprotectin diagnostics, offering fCAL ELISA, fCAL turbo, Quantum Blue, and IBDoc testing solutions. Its portfolio covers conventional laboratory testing, automated assays, rapid testing, and home-based IBD monitoring. The company's products support intestinal inflammation assessment and repeated monitoring of Crohn's disease and ulcerative colitis. Clinical guidelines recognize fecal calprotectin concentrations below 150 µg/g, alongside clinical remission, as useful for ruling out active inflammation in selected IBD patients, highlighting the clinical relevance of its testing portfolio. Thermo Fisher Scientific Inc. – Established Provider of Laboratory-Based Calprotectin Diagnostics Thermo Fisher Scientific participates in fecal calprotectin diagnostics through its EliA Calprotectin assay, supporting quantitative testing in clinical laboratories. Its established immunodiagnostic platforms and laboratory relationships strengthen its competitive position. Fecal calprotectin testing commonly uses 50 µg/g as an initial reference threshold, although interpretation varies by assay and clinical setting. The company's laboratory-focused offering is relevant to gastrointestinal inflammation assessment and IBD monitoring. Other Key Companies: Roche Diagnostics: A major diagnostic laboratory technology provider with automated testing platforms and clinical laboratory relationships relevant to gastrointestinal diagnostics. Abbott Laboratories: An established immunoassay and diagnostic systems manufacturer with laboratory infrastructure relevant to gastrointestinal testing services. Bio-Rad Laboratories, Inc.: Provides laboratory testing technologies and quality-control solutions that support diagnostic accuracy and standardized laboratory operations. Analyst Commentary: Where Can Suppliers Grow as Repeat Testing Moves Across Care Settings? The fecal calprotectin test market offers strong opportunities in rapid testing, automated immunoassays, and home-based IBD monitoring. Manufacturers offering reliable quantitative results, convenient sample collection, and compatibility with established laboratory services are well-positioned to strengthen their presence in gastrointestinal diagnostics. Repeated testing for long-term IBD management remains a key source of recurring commercial opportunities. Fecal Calprotectin Test Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 237 Million Revenue Forecast in 2032 USD 411.6 Million Overall Growth Rate CAGR of 8.2% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Product Type, By Test Method, By Application, By End User, By Geography By Product Type ELISA Test Kits, Rapid Test Kits, Automated Immunoassay Kits By Test Method Laboratory-Based Testing, Point-of-Care Testing, Home-Based Testing By Application Inflammatory Bowel Disease Monitoring, Inflammatory Bowel Disease Diagnosis, Differentiation of Inflammatory Bowel Disease and Irritable Bowel Syndrome By End User Diagnostic Laboratories, Hospitals and Clinics, Home Care Settings By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Use of stool testing to assess suspected inflammatory bowel disease, repeat monitoring of Crohn’s disease and ulcerative colitis, and wider availability of rapid tests and automated laboratory assays Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are driving demand across the market? A1. Demand is supported by increasing inflammatory bowel disease diagnoses, recurring disease-monitoring requirements, and growing use of non-invasive stool tests for assessing intestinal inflammation. Q2. Why are rapid test kits gaining importance in the industry? A2. Rapid test kits are projected to record the fastest product-type CAGR of 10.2% during 2026–2032. Shorter turnaround times and convenient testing procedures are encouraging adoption in outpatient and point-of-care settings. Q3. Which application represents the largest revenue opportunity in the market? A3. IBD monitoring accounts for the largest application share at 44% in 2025. Repeated testing to assess treatment response, identify disease flare-ups, and monitor intestinal inflammation supports its leading position. Q4. How is home-based testing influencing the industry? A4. Home-based testing is projected to record the fastest test-method CAGR of 12.0% during 2026–2032. Convenient stool sample collection and remote monitoring are supporting its adoption among patients with Crohn's disease and ulcerative colitis. Q5. Which end-user segment offers the strongest growth opportunity? A5. Home care settings are projected to record the fastest end-user CAGR of 10.5% during 2026–2032. Increasing demand for convenient sample collection and long-term monitoring is supporting expansion. Q6. Which region is expected to record the fastest growth in the market? A6. Asia-Pacific is projected to record the fastest regional CAGR of 10.3% during 2026–2032. Growing gastrointestinal diagnostic services and increasing adoption of non-invasive testing across China, India, and Japan are supporting regional expansion. Sources: CDC National Center for Health Statistics — 4.11 million U.S. adults reported having ever been diagnosed with IBD in the 2023–2024 survey. CDC — Inflammatory Bowel Disease Among U.S. Adults, 2023–2024 Global Burden of Disease analyses — An estimated 3.83 million people worldwide had IBD in 2021, with 375,140 new cases. PubMed — Global IBD Burden in 2021 · PubMed Central — Asia IBD Burden in 2023 American Gastroenterological Association — Biomarker monitoring may be performed every 6–12 months in Crohn’s disease patients in symptomatic remission. AGA — Crohn’s Disease Biomarker Guideline · AGA — Ulcerative Colitis Biomarker Guideline NICE and Mayo Clinic Laboratories — 50 µg/g is a reference threshold for evaluating suspected intestinal inflammation. NICE — Fecal Calprotectin Thresholds and Diagnostic Considerations · Mayo Clinic Laboratories — Fecal Calprotectin Test Interpretation ALPCO and U.S. FDA — The fecal calprotectin immunoturbidimetric assay launched commercially in Europe in May 2025. ALPCO — European Launch and U.S. Trial Announcement · FDA — ALPCO Clinical Performance Review · ClinicalTrials.gov — Automated ALPCO Assay Study QuidelOrtho and BÜHLMANN — fCAL turbo became available on three VITROS analyzer models in July 2025. QuidelOrtho — fCAL Turbo Availability on VITROS Systems U.S. FDA and Roche — The FDA recorded a high-complexity CLIA categorization for fCAL turbo on the cobas c 703 analyzer on July 29, 2026. FDA — July 2026 Roche cobas c 703 CLIA Record · FDA — fCAL Turbo 510(k) Clearance BÜHLMANN — Its portfolio includes an FDA-cleared laboratory ELISA, a 12–15-minute rapid test, and a smartphone-based home test. FDA — BÜHLMANN fCAL ELISA Clearance · BÜHLMANN — Quantum Blue Rapid Calprotectin Tests · BÜHLMANN — IBDoc Home Test and Availability 2026 PROMOTE UC trial — Symptomatic flares occurred in 32% of both the home-testing and standard-care groups. PubMed — 2026 Randomized Trial of Home Fecal Calprotectin Monitoring Thermo Fisher Scientific, DiaSorin, and Euroimmun — Direct product sources for the competitive landscape. Thermo Fisher — EliA Calprotectin 2 · DiaSorin — LIAISON Calprotectin · Euroimmun — Calprotectin ELISA · BÜHLMANN — Analyzer Compatibility Montana Medicaid — The January 2026 laboratory fee schedule lists USD 19.63 for fecal calprotectin under CPT 83993. Montana Medicaid — January 2026 Laboratory Services Fee Schedule Table of Contents - Global Fecal Calprotectin Test Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Test Method, Application, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Test Method, Application, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Test Method, Application, and End User Investment Opportunities in the Fecal Calprotectin Test Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in ELISA Test Kits, Rapid Test Kits, Automated Immunoassay Kits, Laboratory-Based Testing, Point-of-Care Testing, and Home-Based Testing Opportunities in Inflammatory Bowel Disease Monitoring, Inflammatory Bowel Disease Diagnosis, and IBD–IBS Differentiation Growth Opportunities in Automated Assays, Analyzer Compatibility, and Remote IBD Monitoring Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Clinical Importance of Fecal Calprotectin Testing in Intestinal Inflammation Assessment Role of Fecal Calprotectin Testing in Crohn's Disease and Ulcerative Colitis Diagnosis and Monitoring Use of Fecal Calprotectin Testing in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome Importance of Repeat Testing, Treatment Response Assessment, and Long-Term Patient Monitoring Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Historical Data Assessment (2019–2024) Base Year Market Assessment (2025) Forecast Modeling and Market Validation (2026–2032) Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory, Clinical Guideline, and Reimbursement Factors Role of Increasing Inflammatory Bowel Disease Diagnoses and Recurring Monitoring Requirements in Market Expansion Impact of Automated Assays, Rapid Testing Systems, and Laboratory Analyzer Compatibility Growing Demand for Non-Invasive Intestinal Inflammation Assessment Influence of Home-Based Sample Collection and Remote IBD Monitoring Diagnostic Accuracy, Testing Utilization, and Access to Gastroenterology Services Global Fecal Calprotectin Test Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: ELISA Test Kits Rapid Test Kits Automated Immunoassay Kits Market Analysis by Test Method: Laboratory-Based Testing Point-of-Care Testing Home-Based Testing Market Analysis by Application: Inflammatory Bowel Disease (IBD) Monitoring Inflammatory Bowel Disease Diagnosis Differentiation of Inflammatory Bowel Disease and Irritable Bowel Syndrome (IBS) Market Analysis by End User: Diagnostic Laboratories Hospitals and Clinics Home Care Settings Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Fecal Calprotectin Test Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Test Method, Application, and End User Country-Level Breakdown: United States Canada Mexico Europe Fecal Calprotectin Test Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Test Method, Application, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific Fecal Calprotectin Test Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Test Method, Application, and End User Country-Level Breakdown: China India Japan South Korea Rest of Asia-Pacific Latin America Fecal Calprotectin Test Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Test Method, Application, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Fecal Calprotectin Test Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Test Method, Application, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: BÜHLMANN Laboratories AG ALPCO QuidelOrtho Corporation DiaSorin S.p.A. Thermo Fisher Scientific Inc. Euroimmun AG Roche Diagnostics Abbott Laboratories Bio-Rad Laboratories, Inc. Siemens Healthineers AG Danaher Corporation QIAGEN N.V. Hologic, Inc. Competitive Landscape and Strategic Insights Benchmarking Based on Assay Performance, Diagnostic Accuracy, Automation, Analyzer Compatibility, and Regional Presence Product Portfolio and Fecal Calprotectin Assay Positioning ELISA, Rapid Testing, and Automated Immunoassay Product Strategies Laboratory-Based and Point-of-Care Testing Capabilities Home-Based Testing and Remote IBD Monitoring Strategies Clinical Validation, Regulatory Compliance, and Diagnostic Quality Assessment Strategic Partnerships and Laboratory Analyzer Integration Recent Product Launches and Diagnostic Technology Developments (2025–2026) Appendix Abbreviations and Terminologies Used in the Report References and Sources Clinical Guidelines and Diagnostic Reference Materials Market Definitions and Segmentation Scope Historical Data Coverage (2019–2024) Base Year Definitions and Assumptions (2025) Forecast Methodology and Assumptions (2026–2032) List of Tables Market Size by Product Type, Test Method, Application, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Leading Fecal Calprotectin Test Vendors Product Portfolio and Assay Technology Comparison Laboratory-Based, Point-of-Care, and Home-Based Testing Analysis Clinical Applications in IBD Monitoring, IBD Diagnosis, and IBD–IBS Differentiation Diagnostic Assay Developments and Laboratory Analyzer Compatibility (2025–2026) List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Test Method, Application, and End User (2025 vs. 2032) Global Fecal Calprotectin Test Market Ecosystem and Value Chain Analysis Fecal Calprotectin Testing Workflow Across Laboratory, Point-of-Care, and Home-Based Settings Clinical Use of Fecal Calprotectin in IBD Monitoring and IBD–IBS Differentiation